Management of Shiga toxin-associated Escherichia coli-induced haemolytic uraemic syndrome: Randomized clinical trials are needed

Nephrology Dialysis Transplantation

Volumn 27, Issue 10, 2012, Pages 3669-3674

  Karpman, Diana ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTIINFECTIVE AGENT; BACTERIUM LIPOPOLYSACCHARIDE; CORTICOSTEROID; DIURETIC AGENT; ECULIZUMAB; ESCHERICHIA COLI O157 VACCINE; GLOBOTRIOSE RECEPTOR DERIVATIVE; ISOTONIC SOLUTION; MENINGITIS VACCINE; SHIGA TOXIN; SHIGA TOXIN MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ACIDOSIS; ACUTE KIDNEY FAILURE; ANTIBACTERIAL ACTIVITY; ANURIA; ARTERY THROMBOSIS; BACTERIAL COLONIZATION; BACTERIAL MENINGITIS; BACTERIAL SURVIVAL; BACTERIAL VIRULENCE; BACTERIOPHAGE; BLOODY DIARRHEA; CONSERVATIVE TREATMENT; DIARRHEA; DRUG APPROVAL; DRUG BINDING; DRUG INDICATION; DRUG TOLERABILITY; EDITORIAL; ENTEROPATHOGENIC ESCHERICHIA COLI; ENTEROPATHOGENIC ESCHERICHIA COLI INFECTION; EPIDEMIC; ESCHERICHIA COLI; ESCHERICHIA COLI O104; ESCHERICHIA COLI O157; HEMODIALYSIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERKALEMIA; HYPERVOLEMIA; INFLAMMATION; MORTALITY; NONHUMAN; PARENTERAL NUTRITION; PATHOPHYSIOLOGY; PERITONEAL DIALYSIS; PLASMAPHERESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REHYDRATION; STRAIN DIFFERENCE; THROMBOTIC THROMBOCYTOPENIC PURPURA; VEIN THROMBOSIS;

ANTIBODIES, MONOCLONAL, HUMANIZED; ESCHERICHIA COLI INFECTIONS; FEMALE; HEMOLYTIC-UREMIC SYNDROME; HUMANS; MALE; PLASMA EXCHANGE; SHIGA-TOXIGENIC ESCHERICHIA COLI;

EID: 84868585323     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs456     Document Type: Editorial

References (62)

1. Taylor CM. Enterohaemorrhagic Escherichia coli and Shigella dysenteriae type 1-induced haemolytic uraemic syndrome. Pediatr Nephrol 2008; 23: 1425-1431
2. Tschape H, Prager R, Streckel Wet al. Verotoxinogenic Citrobacter freundii associated with severe gastroenteritis and cases of haemolytic uraemic syndrome in a nursery school: green butter as the infection source. Epidemiol Infect 1995; 114: 441-450
3. Kielstein JT, Beutel G, Fleig S et al. Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga toxinproducing E. coli O104:H4-induced hemolytic uremic syndrome: an analysis of the German STEC-HUS registry. Nephrol Dial Transplant 2012; 27: 3807-3815
4. Phillips AD, Navabpour S, Hicks S et al. Enterohaemorrhagic Escherichia coli O157:H7 target Peyer's patches in humans and cause attaching/effacing lesions in both human and bovine intestine. Gut 2000; 47: 377-381
5. Pacheco AR, Sperandio V. Inter-kingdom signaling: chemical language between bacteria and host. Curr Opin Microbiol 2009; 12: 192-198
6. Schuller S, Heuschkel R, Torrente F et al. Shiga toxin binding in normal and inflamed human intestinal mucosa. Microbes Infect 2007; 9: 35-39
7. Hurley BP, Thorpe CM, Acheson DW. Shiga toxin translocation across intestinal epithelial cells is enhanced by neutrophil transmigration. Infect Immun 2001; 69: 6148-6155
8. Fontaine A, Arondel J, Sansonetti PJ. Role of Shiga toxin in the pathogenesis of bacillary dysentery, studied by using a Toxmutant of Shigella dysenteriae 1. Infect Immun 1988; 56: 3099-3109
9. Békássy ZD, Calderon Toledo C, Leoj G et al. Intestinal damage in enterohemorrhagic Escherichia coli infection. Pediatr Nephrol 2011; 26: 2059-2071
10. Calderon Toledo C, Rogers TJ, Svensson M et al. Shiga toxinmediated disease in MyD88-deficient mice infected with Escherichia coli O157:H7. Am J Pathol 2008; 173: 1428-1439
11. Te Loo DM, van Hinsbergh VW, van den Heuvel LP et al. Detection of verocytotoxin bound to circulating polymorphonuclear leukocytes of patients with hemolytic uremic syndrome. J Am Soc Nephrol 2001; 12: 800-806
12. Brigotti M, Tazzari PL, Ravanelli E et al. Clinical relevance of Shiga toxin concentrations in the blood of patients with hemolytic uremic syndrome. Ped Inf Dis J 2011; 30: 486-490
13. Ståhl AL, Svensson M, Morgelin M et al. Lipopolysaccharide from enterohemorrhagic Escherichia coli binds to platelets through TLR4 and CD62 and is detected on circulating platelets in patients with hemolytic uremic syndrome. Blood 2006; 108: 167-176
14. Ståhl AL, Sartz L, Nelsson A et al. Shiga toxin and lipopolysaccharide induce platelet-leukocyte aggregates and tissue factor release, a thrombotic mechanism in hemolytic uremic syndrome. PLoS ONE 2009; 4: e6990
15. Ståhl AL, Sartz L, Karpman D. Complement activation on plateletleukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Blood 2011; 117: 5503-5513
16. Ge S, Hertel B, Emden SH et al. Microparticle generation and leucocyte death in Shiga toxin-mediated HUS. Nephrol Dial Transplant 2012; 27: 2768-2775
17. te Loo DM, Monnens LA, van Der Velden TJ et al. Binding and transfer of verocytotoxin by polymorphonuclear leukocytes in hemolytic uremic syndrome. Blood 2000; 95: 3396-3402
18. Brigotti M, Tazzari PL, Ravanelli E et al. Endothelial damage induced by Shiga toxins delivered by neutrophils during transmigration. J Leukoc Biol 2010; 88: 201-210
19. Zoja C, Buelli S, Morigi M. Shiga toxin-associated hemolytic uremic syndrome: pathophysiology of endothelial dysfunction. Pediatr Nephrol 25: 2231-2240
20. Nestoridi E, Tsukurov O, Kushak RI et al. Shiga toxin enhances functional tissue factor on human glomerular endothelial cells: implications for the pathophysiology of hemolytic uremic syndrome. J Thromb Haemostas 2005; 3: 752-762
21. Karpman D, Hakansson A, Perez MT et al. Apoptosis of renal cortical cells in the hemolytic-uremic syndrome: in vivo and in vitro studies. Infect Immun 1998; 66: 636-644
22. Obata F, Tohyama K, Bonev AD et al. Shiga toxin 2 affects the central nervous system through receptor globotriaosylceramide localized to neurons. J Infect Dis 2008; 198: 1398-1406
23. Hickey CA, Beattie TJ, Cowieson J et al. Early volume expansion during diarrhea and relative nephroprotection during subsequent hemolytic uremic syndrome. Arch Pediatr Adolesc Med 2011; 165: 884-889
24. Loirat C, Saland J, Bitzan M. Management of hemolytic uremic syndrome. Presse Med 2012; 41: e115-e135
25. Bitzan M, Schaefer F, Reymond D. Treatment of typical (enteropathic) hemolytic uremic syndrome. Semin Thrombos Hemostas 2010; 36: 594-610
26. Loos S, Ahlenstiel T, Kranz B et al. An outbreak of Shiga toxinproducing Escherichia coli O104:H4 hemolytic uremic syndrome in Germany: presentation and short-term outcome in children. Clin Infect Dis 2012; 55: 753-759
27. Wong CS, Mooney JC, Brandt JR et al. Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: a multivariable analysis. Clin Inf Dis 2012; 55: 33-41
28. Menne J, Nitschke M, Stingele R et al. Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. Br Med J 2012; 345: e4565
29. Rizzoni G, Claris-Appiani A, Edefonti A et al. Plasma infusion for hemolytic-uremic syndrome in children: results of a multicenter controlled trial. J Pediatr 1988; 112: 284-290
30. Nakatani T, Tsuchida K, Yoshimura R et al. Plasma exchange therapy for the treatment of Escherichia coli O-157 associated hemolytic uremic syndrome. Int J Mol Med 2002; 10: 585-588
31. Colic E, Dieperink H, Titlestad K et al. Management of an acute outbreak of diarrhoea-associated haemolytic uraemic syndrome with early plasma exchange in adults from southern Denmark: an observational study. Lancet 2011; 378: 1089-1093
32. Michael M, Elliott EJ, Ridley GF et al. Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura. Cochrane Database Syst Rev 2009: CD003595
33. Lapeyraque AL, Malina M, Fremeaux-Bacchi V et al. Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med 2011; 364: 2561-2563
34. Monnens L, Molenaar J, Lambert PH et al. The complement system in hemolytic-uremic syndrome in childhood. Clin Nephrol 1980; 13: 168-171
35. Thurman JM, Marians R, Emlen W et al. Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 2009; 4: 1920-1924
36. Ueki T, Mizuno M, Uesu T et al. Distribution of activated complement, C3b, and its degraded fragments, iC3b/C3dg, in the colonic mucosa of ulcerative colitis. Clin Exp Immunol 1996; 104: 286-292
37. Chen G, Yang Y, Gao X et al. Blockade of complement activation product C5a activity using specific antibody attenuates intestinal damage in trinitrobenzene sulfonic acid induced model of colitis. Lab Invest 2011; 91: 472-483
38. Frank C, Werber D, Cramer JP et al. Epidemic profile of Shigatoxin-producing Escherichia coli O104:H4 outbreak in Germany. N Engl J Med 2011; 365: 1771-1780
39. German EHEC-HUS Registry. The German 2011 epidemic of Shiga toxin-producing E. coli-the nephrological view. Nephrol Dial Transplant 2011; 26: 2723-2726
40. Ake JA, Jelacic S, Ciol MA et al. Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion. Pediatrics 2005; 115: e673-e680
41. Rousseau E, Blais N, O'Regan S. Decreased necessity for dialysis with loop diuretic therapy in hemolytic uremic syndrome. Clin Nephrol 1990; 34: 22-25
42. Karpman D. Haemolytic uremic syndrome and thrombotic thrombocytopenic purpura. Current Paediatr 2002; 12: 569-574
43. George JN, Vesely SK. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: diagnosis and treatment. Cleve Clin J Med 2001; 68: 857-858
44. Trachtman H, Cnaan A, Christen E et al. Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: a randomized controlled trial. J Am Med Assoc 2003; 290: 1337-1344
45. Wong CS, Jelacic S, Habeeb RL et al. The risk of the hemolyticuremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med 2000; 342: 1930-1936
46. Dundas S, Murphy J, Soutar RL et al. Effectiveness of therapeutic plasma exchange in the 1996 Lanarkshire Escherichia coli O157:H7 outbreak. Lancet 1999; 354: 1327-1330
47. Greinacher A, Friesecke S, Abel P et al. Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: a prospective trial. Lancet 2011; 378: 1166-1173
48. Van Damme-Lombaerts R, Proesmans W, Van Damme B et al. Heparin plus dipyridamole in childhood hemolytic-uremic syndrome: a prospective, randomized study. J Pediatr 1988; 113: 913-918
49. Loirat C, Beaufils F, Sonsino E et al. Treatment of childhood hemolytic-uremic syndrome with urokinase. Cooperative controlled trial. Arch Fr Pediatr 1984; 41: 15-19
50. Sorrenti LY, Lewy PR. The hemolytic-uremic syndrome: experience at a center in the Midwest. Am J Dis Child 1978; 132: 59-62
51. Perez N, Spizzirri F, Rahman R et al. Steroids in the hemolytic uremic syndrome. Pediatr Nephrol 1998; 12: 101-104
52. Bitzan M, Poole R, Mehran M et al. Safety and pharmacokinetics of chimeric anti-Shiga toxin 1 and anti-Shiga toxin 2 monoclonal antibodies in healthy volunteers. Antimicrob Agents Chemother 2009; 53: 3081-3087
53. Lopez EL, Contrini MM, Glatstein E et al. Safety and pharmacokinetics of urtoxazumab, a humanized monoclonal antibody, against Shiga-like toxin 2 in healthy adults and in pediatric patients infected with Shiga-like toxin-producing Escherichia coli. Antimicrob Agents Chemother 2010; 54: 239-243
54. Dowling TC, Chavaillaz PA, Young DG et al. Phase 1 safety and pharmacokinetic study of chimeric murine-human monoclonal antibody c alpha Stx2 administered intravenously to healthy adult volunteers. Antimicrob Agents Chemother 2005; 49: 1808-1812
55. Mulvey GL, Marcato P, Kitov PI et al. Assessment in mice of the therapeutic potential of tailored, multivalent Shiga toxin carbohydrate ligands. J Infect Dis 2003; 187: 640-649
56. Watanabe M, Matsuoka K, Kita E et al. Oral therapeutic agents with highly clustered globotriose for treatment of Shiga toxigenic Escherichia coli infections. J Infect Dis 2004; 189: 360-368
57. Mukhopadhyay S, Linstedt AD. Manganese blocks intracellular trafficking of Shiga toxin and protects against Shiga toxicosis. Science 2012; 335: 332-335
58. Ahmed A, Li J, Shiloach Y et al. Safety and immunogenicity of Escherichia coli O157 O-specific polysaccharide conjugate vaccine in 2-5-year-old children. J Infect Dis 2006; 193: 515-521
59. Wen SX, Teel LD, Judge NA et al. A plant-based oral vaccine to protect against systemic intoxication by Shiga toxin type 2. Proc Natl Acad Sci 2006; 103: 7082-7087
60. Gao X, Cai K, Shi J et al. Immunogenicity of a novel Stx2BStx1B fusion protein in a mice model of Enterohemorrhagic Escherichia coli O157:H7 infection. Vaccine 2009; 27: 2070-2076
61. Gu J, Liu Y, Yu S et al. Enterohemorrhagic Escherichia coli trivalent recombinant vaccine containing EspA, intimin and Stx2 induces strong humoral immune response and confers protection in mice. Microbes Infect 2009; 11: 835-841
62. Bentancor LV, Bilen M, Brando RJ et al. A DNA vaccine encoding the enterohemorragic Escherichia coli Shiga-like toxin 2 A2 and B subunits confers protective immunity to Shiga toxin challenge in the murine model. Clin Vaccine Immunol 2009; 16: 712-718